2021年10月15日 · Factor XI (FXI) is the zymogen of a plasma protease, factor XIa (FXIa), that contributes to thrombin generation during blood coagulation by proteolytic activation of several coagulation factors, most notably factor IX (FIX). FXI is a homolog of ...

2024年4月11日 · Domain-specific FXI inhibitors. This figure distinguishes the domains of FXI by color: A1 (orange), A2 (pink), A3 (blue), A4 (green), and catalytic (purple). Use of domain-specific inhibitors sheds light on residues that mediate ligand binding.

2024年4月8日 · 项目名称：FXI双表位双特异性抗体. 分子类型：人源化抗体. 分子机制：抑制 XI 活性，阻断内源性凝血通路. 适应症：静脉血栓栓塞. 进展阶段：临床前候选药物. 合作模式：合作开发或转让许可. 项目亮点. Competitive advantage. 单抗分子体外功能活性优于 Abelacimab

fxi 是脊椎动物血浆凝固中相对较新的成员，是同二聚体，每个亚基包含四个苹果结构域和一个蛋白酶结构域。 苹果结构域形成盘状结构，具有血小板、高分子量激肽原和底物因子 IX (FIX) 的结合位点。

2010年4月1日 · Factor XI (FXI) is the zymogen of an enzyme (FXIa) that contributes to hemostasis by activating factor IX. Although bleeding associated with FXI deficiency is relatively mild, there has been resurgence of interest in FXI because of studies indicating it makes contributions to thrombosis and other processes associated with dysregulated coagulation.

2021年1月11日 · 大量临床资料表明，先天缺乏凝血因子XI（factor XI，FXI）的患者患缺血性脑卒中及深静脉血栓的比率明显降低，且一般无自发性出血。由于FXI的这一特点，对新抗凝方案探索的目光聚焦到了FXI抑制剂的开发上。以FXI为靶点的抗血栓新药研究已取得一定进展。

The coagulation protease zymogen factor (F)XI is a disulfide bond-linked homodimer, a configuration that is necessary for protein secretion and function. The non-catalytic portion of the FXI polypeptide contains four repeats called apple domains (A1-A4). It …

2024年4月16日 · Xisomab binds to FXI and to the A2 domain thereby preventing FXI activation by FXIIa . The other functions of FXI are not impacted. Monoclonal antibodies exhibit a rapid onset of action and a prolonged duration, with effects lasting over a month. Their metabolism relies mainly on the reticuloendothelial system . In situations where their ...

2025年2月1日 · We identified the FXI binding domains in 2 patients with severe acquired FXI deficiency. The autoantibody in patient 1 targeted the FXI catalytic domain. The autoantibody in patient 2 was likely oligoclonal and recognized the FXI A2 and A3 domains. Factor (F)XI is a zymogen that contributes to thrombin generation through activation of FIX.

Factor XI (FXI) contributes to thrombotic disease while playing a limited role in normal hemostasis. We generated a unique, humanized anti-FXI antibody, AB023, which blocks factor XIIa (FXIIa)-mediated FXI activation without inhibiting FXI activation by thrombin or the procoagulant function of FXIa.